18 citations
,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
8 citations
,
July 2022 in “International Journal of Molecular Sciences” 17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.
7 citations
,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
14 citations
,
December 2010 in “Seminars in Oncology” Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” Estrogen speeds up hair follicle cell death, causing early hair growth cycle changes, but only if a specific receptor is present.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
2 citations
,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
June 2023 in “Journal of multidisciplinary sciences (Online)” PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
23 citations
,
September 2015 in “International Journal of Molecular Medicine” Activating ER-β, not ER-α, improves skin cell growth and wound healing.
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” 17α-estradiol extends lifespan and improves metabolism in male mice through the estrogen receptor α.
19 citations
,
December 2011 in “PubMed” Inflammation and immunity play a key role in androgenetic alopecia, with better treatment outcomes in certain immune-positive cases.
150 citations
,
April 2013 in “Dermato-endocrinology” Estrogen therapy can reduce skin aging but has cancer risks.
34 citations
,
November 2017 in “Gynecological Endocrinology” A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
58 citations
,
January 2003 in “Thrombosis and Haemostasis” Testosterone may slow down wound healing and increase inflammation.
March 2013 in “Journal für Kardiologie (Krause & Pachernegg GmbH)” Hormones significantly affect hair growth and loss, with potential for new treatments.
5 citations
,
August 2012 in “Journal of Dermatology” Tamoxifen may cause female hair loss by increasing androgen receptor expression.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
19 citations
,
June 2001 in “Annals of Internal Medicine” Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
2 citations
,
March 2025 in “ESMO Open” Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
9 citations
,
January 2016 in “Skin Pharmacology and Physiology” The study concluded that both estrogen and androgen receptors, which decrease with age, are linked to skin aging and may be hormonally regulated.
6 citations
,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
130 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” Estrogen Receptor ß (ERß) is the main hormone controller in human skin and hair follicles, not Estrogen Receptor α (ERα) or the Androgen Receptor (AR).
93 citations
,
June 2001 in “The Journal of Clinical Endocrinology and Metabolism” Certain genetic variations in the AR and ERβ genes can affect androgen levels in women.